- Home
- Next Generation Sequencing Ngs Market
Global Next Generation Sequencing (NGS) Market - Industry Trends and Forecast to 2030
- Published Date: September, 2022 | Report ID: CLS-216 | No of pages: 232 | Format:
Global next generation sequencing (NGS) market is projected to register a CAGR of 17.1% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Market Segmentation:
Global Next Generation Sequencing (NGS) Market, By Product (Instruments, Consumables and Services), Applications (Diagnostics, Biomarker Discovery, Precision Medicine, Drug Discovery, Agriculture and Animal Research and Others), End User (Pharmaceutical & Biotechnology Companies, Research Centers & Academic and Government Institutes and Hospital & Clinics), Country (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Switzerland, Russia, Turkey, Belgium, Netherlands and Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, Brazil, Argentina and Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E, Israel and Rest of Middle East And Africa) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the global next generation sequencing (NGS) market are:
Decrease in the cost of genetic sequencing per base
Increase in the adoption of genome-focused pharmacology
Wide product portfolio offered by major player
Market Players:
The key market players for global next generation sequencing (NGS) market are listed below:
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
QIAGEN
Illumina, Inc.
Bio-Rad Laboratories, Inc.
Roche Sequencing (A subsidiary of F. Hoffman La Roche)
BGI (A subsidiary of BGI Group)
Oxford Nanopore Technologies plc
MACROGEN CO., LTD.
DNASTAR
Geneious
Partek Incorporated
PerkinElmer Inc.
Takara Bio Inc.
bioMrieux SA
Pacific Biosciences of California, Inc.
GENEWIZ
10x Genomics
New England Biolabs
Hamilton Company
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW OF GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET 23
1.4 CURRENCY AND PRICING 25
1.5 LIMITATIONS 25
1.6 MARKETS COVERED 25
2 MARKET SEGMENTATION 28
2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 30
2.4 DBMR TRIPOD DATA VALIDATION MODEL 31
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.6 MULTIVARIATE MODELLING 35
2.7 MARKET APPLICATION COVERAGE GRID 35
2.8 PRODUCT TYPE LIFELINE CURVE 36
2.9 DBMR MARKET POSITION GRID 37
2.10 VENDOR SHARE ANALYSIS 38
2.11 SECONDARY SOURCES 39
2.12 ASSUMPTIONS 39
3 EXECUTIVE SUMMARY 40
3.1 PESTEL'S ANALYSIS 44
3.2 PORTER'S FIVE FORCES MODEL 45
4 REGULATIONS OF GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET 46
5 MARKET OVERVIEW 49
5.1 DRIVERS 51
5.1.1 DECREASE IN THE COST OF GENETIC SEQUENCING PER BASE 51
5.1.2 INCREASE IN THE ADOPTION OF GENOME-FOCUSED PHARMACOLOGY 52
5.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY MAJOR PLAYER 53
5.1.4 USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT 53
5.1.5 INCREASED TREND TOWARDS PERSONALIZED MEDICATION 54
5.2 RESTRAINTS 55
5.2.1 HIGH COST OF INSTRUMENT 55
5.2.2 DIFFICULTY IN CLINICAL NGS DATA ANALYSIS 55
5.2.3 CYBER SECURITY CONCERN IN GENOMICS 56
5.3 OPPORTUNITIES 56
5.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 56
5.3.2 PRODUCT APPROVAL IN RECENT YEARS 57
5.3.3 ADVANCEMENT IN NGS TECHNOLOGY 57
5.4 CHALLENGES 58
5.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM NGS 58
5.4.2 CHALLENGES FOR IMPLEMENTING NGS IN THE CLINICAL LAB 58
6 IMPACT OF COVID-19 ON GLOBAL NEXT GENERATION SEQUENCING (NGS) HEALTHCARE INDUSTRY 60
6.1 IMPACT ON PRICE 60
6.2 IMPACT ON DEMAND 60
6.3 IMPACT ON SUPPLY CHAIN 61
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19 62
6.5 CONCLUSION 62
7 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT 63
7.1 OVERVIEW 64
7.2 INSTRUMENTS 66
7.2.1 HISEQ SERIES 68
7.2.2 MISEQ SERIES 68
7.2.3 ION TORRENT 68
7.2.4 PACBIO RS II 68
7.2.5 SEQUEL SYSTEM 68
7.2.6 SOLID 68
7.2.7 OTHERS 68
7.3 CONSUMABLE 68
7.3.1 LIBRARY PREPARATION & TARGET ENRICHMENT 69
7.3.2 SAMPLE PREPARATION CONSUMABLES 69
7.3.3 OTHERS 70
7.4 SERVICES 70
7.4.1 SEQUENCING SERVICES 71
7.4.2 DATA MANAGEMENT 71
8 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION 72
8.1 OVERVIEW 73
8.2 DIAGNOSTICS 76
8.3 BIOMARKER DISCOVERY 76
8.4 PRECISION MEDICINE 77
8.5 DRUG DISCOVERY 78
8.6 AGRICULTURE & ANIMAL RESEARCH 79
9 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER 81
9.1 OVERVIEW 82
9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 85
9.3 RESEARCH CENTERS & ACADEMIC AND GOVERNMENT INSTITUTES 86
9.4 HOSPITAL & CLINICS 86
10 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION 88
10.1 OVERVIEW 89
10.2 NORTH AMERICA 94
10.2.1 U.S. 101
10.2.2 CANADA 103
10.2.3 MEXICO 105
10.3 EUROPE 107
10.3.1 GERMANY 114
10.3.2 FRANCE 116
10.3.3 U.K. 118
10.3.4 ITALY 120
10.3.5 RUSSIA 122
10.3.6 SPAIN 124
10.3.7 SWITZERLAND 126
10.3.8 NETHERLANDS 128
10.3.9 BELGIUM 130
10.3.10 TURKEY 132
10.3.11 REST OF EUROPE 134
10.4 ASIA-PACIFIC 135
10.4.1 CHINA 142
10.4.2 JAPAN 144
10.4.3 INDIA 146
10.4.4 SOUTH KOREA 148
10.4.5 AUSTRALIA 150
10.4.6 SINGAPORE 152
10.4.7 THAILAND 154
10.4.8 MALAYSIA 156
10.4.9 INDONESIA 158
10.4.10 PHILIPPINES 160
10.4.11 REST OF ASIA-PACIFIC 162
10.5 SOUTH AMERICA 163
10.5.1 BRAZIL 170
10.5.2 REST OF SOUTH AMERICA 172
10.6 MIDDLE EAST AND AFRICA 173
10.6.1 SOUTH AFRICA 180
10.6.2 REST OF MIDDLE EAST AND AFRICA 182
11 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY LANDSCAPE 183
11.1 COMPANY SHARE ANALYSIS: GLOBAL 183
11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 184
11.3 COMPANY SHARE ANALYSIS: EUROPE 185
11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 186
12 COMPANY PROFILING 187
12.1 ILLUMINA, INC. 187
12.1.1 COMPANY SNAPSHOT 187
12.1.2 REVENUE ANALYSIS 188
12.1.3 COMPANY SHARE ANALYSIS 188
12.1.4 SWOT ANALYSIS 189
12.1.5 PRODUCT PORTFOLIO 189
12.1.6 RECENT DEVELOPMENTS 190
12.2 BGI (A SUBSIDIAIRY OF BGI GROUP) (2021) 191
12.2.1 COMPANY SNAPSHOT 191
12.2.2 REVENUE ANALYSIS 191
12.2.3 COMPANY SHARE ANALYSIS 192
12.2.4 SWOT ANALYSIS 192
12.2.5 PRODUCT PORTFOLIO 193
12.2.6 RECENT DEVELOPMENT 193
12.3 THERMO FISHER SCIENTIFIC INC. 194
12.3.1 COMPANY SNAPSHOT 194
12.3.2 REVENUE ANALYSIS 194
12.3.3 COMPANY SHARE ANALYSIS 195
12.3.4 SWOT ANALYSIS 195
12.3.5 PRODUCT PORTFOLIO 196
12.3.6 RECENT DEVELOPMENTS 196
12.4 QIAGEN 197
12.4.1 COMPANY SNAPSHOT 197
12.4.2 REVENUE ANALYSIS 197
12.4.3 COMPANY SHARE ANALYSIS 198
12.4.4 SWOT ANALYSIS 198
12.4.5 PRODUCT PORTFOLIO 199
12.4.6 RECENT DEVELOPMENTS 200
12.5 AGILENT TECHNOLOGIES, INC. 201
12.5.1 COMPANY SNAPSHOT 201
12.5.2 REVENUE ANALYSIS 201
12.5.3 COMPANY SHARE ANALYSIS 202
12.5.4 SWOT ANALYSIS 202
12.5.5 PRODUCT PORTFOLIO 203
12.5.6 RECENT DEVELOPMENT 203
12.6 OXFORD NANOPORE TECHNOLOGIES 204
12.6.1 COMPANY SNAPSHOT 204
12.6.2 PRODUCT PORTFOLIO 204
12.6.3 RECENT DEVELOPMENTS 205
12.7 BIO-RAD LABORATORIES, INC. 206
12.7.1 COMPANY SNAPSHOT 206
12.7.2 REVENUE ANALYSIS 206
12.7.3 PRODUCT PORTFOLIO 207
12.7.4 RECENT DEVELOPMENTS 207
12.8 10X GENOMICS 208
12.8.1 COMPANY SNAPSHOT 208
12.8.2 REVENUE ANALYSIS 208
12.8.3 PRODUCT PORTFOLIO 209
12.8.4 RECENT DEVELOPMENTS 209
12.9 BIOMRIEUX SA 210
12.9.1 COMPANY SNAPSHOT 210
12.9.2 REVENUE ANALYSIS 210
12.9.3 PRODUCT PORTFOLIO 211
12.9.4 RECENT DEVELOPMENT 211
12.10 DNASTAR 212
12.10.1 COMPANY SNAPSHOT 212
12.10.2 PRODUCT PORTFOLIO 212
12.10.3 RECENT DEVELOPMENT 212
12.11 GENEIOUS 213
12.11.1 COMPANY SNAPSHOT 213
12.11.2 PRODUCT PORTFOLIO 213
12.11.3 RECENT DEVELOPMENTS 213
12.12 GENEWIZ, FROM AZENTA LIFE SCIENCES 214
12.12.1 COMPANY SNAPSHOT 214
12.12.2 REVENUE ANALYSIS 214
12.12.3 PRODUCT PORTFOLIO 215
12.12.4 RECENT DEVELOPMENTS 215
12.13 HAMILTON COMPANY 216
12.13.1 COMPANY SNAPSHOT 216
12.13.2 PRODUCT PORTFOLIO 216
12.13.3 RECENT DEVELOPMENT 216
12.14 MACROGEN, INC. 217
12.14.1 COMPANY SNAPSHOT 217
12.14.2 REVENUE ANALYSIS 217
12.14.3 PRODUCT PORTFOLIO 218
12.14.4 RECENT DEVELOPMENT 218
12.15 NEW ENGLAND BIOLABS 219
12.15.1 COMPANY SNAPSHOT 219
12.15.2 PRODUCT PORTFOLIO 219
12.15.3 RECENT DEVELOPMENT 219
12.16 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 220
12.16.1 COMPANY SNAPSHOT 220
12.16.2 REVENUE ANALYSIS 220
12.16.3 PRODUCT PORTFOLIO 221
12.16.4 RECENT DEVELOPMENTS 221
12.17 PARTEK, INCORPORATED 222
12.17.1 COMPANY SNAPSHOT 222
12.17.2 PRODUCT PORTFOLIO 222
12.17.3 RECENT DEVELOPMENT 222
12.18 PERKIN ELMER INC. (2021) 223
12.18.1 COMPANY SNAPSHOT 223
12.18.2 REVENUE ANALYSIS 223
12.18.3 PRODUCT PORTFOLIO 224
12.18.4 RECENT DEVELOPMENTS 224
12.19 ROCHE SEQUENCING (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD) 225
12.19.1 COMPANY SNAPSHOT 225
12.19.2 REVENUE ANALYSIS (PARENT COMPANY) 225
12.19.3 PRODUCT PORTFOLIO 226
12.19.4 RECENT DEVELOPMENTS 226
12.20 TAKARA BIO INC. 227
12.20.1 COMPANY SNAPSHOT 227
12.20.2 REVENUE ANALYSIS 227
12.20.3 PRODUCT PORTFOLIO 228
12.20.4 RECENT DEVELOPMENTS 228
13 QUESTIONNAIRE 229
14 RELATED REPORTS 232
Segmentation
Short Description
Global Next Generation Sequencing (NGS) Market, By Product (Instruments, Consumables and Services), Applications (Diagnostics, Biomarker Discovery, Precision Medicine, Drug Discovery, Agriculture and Animal Research and Others), End User (Pharmaceutical & Biotechnology Companies, Research Centers & Academic and Government Institutes and Hospital & Clinics), Country (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Switzerland, Russia, Turkey, Belgium, Netherlands and Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, Brazil, Argentina and Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E, Israel and Rest of Middle East And Africa) Industry Trends and Forecast to 2029
Market Definition:
Next generation sequencing or NGS is also known as high-throughput sequencing. It is an exceptional technology which arranges massive DNA strands through huge parallelization. The breakthrough reduces the need for segment cloning that is used in Sanger genome sequencing. The main benefits that NGS provides over Sanger's sequencing methodology are fast procedures, precise performance, and organizational ease even from small sample data. With the development of new technologies and cancer cure treatment, the next-generation sequencing market in clinical oncology has huge potential in the coming years.
Market Segmentation:
Global next generation sequencing (NGS) market is categorized into three notable segments such as product, applications, and end user.
On the basis of product, the global next generation sequencing (NGS) market is segmented into instruments, consumables and services
On the basis of application, the global next generation sequencing (NGS) market is segmented into diagnostics, biomarker discovery, precision medicine, drug discovery, agriculture and animal research and others
On the basis of end-users, the global next generation sequencing (NGS) market is segmented into pharmaceutical & biotechnology companies, research centers & academic and government institutes and hospital & clinics
Market Players
The key market players for global next generation sequencing (NGS) market are listed below:
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
QIAGEN
Illumina, Inc.
Bio-Rad Laboratories, Inc.
Roche Sequencing (A subsidiary of F. Hoffman La Roche)
BGI (A subsidiary of BGI Group)
Oxford Nanopore Technologies plc
MACROGEN CO., LTD.
DNASTAR
Geneious
Partek Incorporated
PerkinElmer Inc.
Takara Bio Inc.
bioMrieux SA
Pacific Biosciences of California, Inc.
GENEWIZ
10x Genomics
New England Biolabs
Hamilton Company
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.